GB1841: In Vitro and In Vivo Data for a Dual Galectin-1/3 Cancer Inhibitor

Fredrik R. Zetterberg published data on GB1841, a halothiazole glycomimetic drug candidate, on figshare in April 2026. The dataset likely contains results from structure-activity relationship (SAR) studies, in vitro ADME parameter optimization, and in vivo efficacy testing in a syngeneic mouse lung cancer model. The file is 3.3 KB in size and is available in CSV format under a CC-BY-NC-4.0 license.

Use Cases

• Analyzing structure-activity relationships (SAR) based on the optimization of 3-(halothiazolyl)triazolyl derivatives.
• Modeling drug affinity based on reported dissociation constants (Kd) for galectin-1 and galectin-3.
• Evaluating in vitro ADME parameters mentioned in the description for early drug candidate profiling.
• Correlating dual galectin inhibition with anti-cancer efficacy based on the described reduction of LL/2 lung cancer cell growth.

Strengths

• Includes specific quantitative binding affinity data (Kd of 0.027/0.14 μM for galectin-1/-3).
• Describes both in vitro ADME parameters and in vivo efficacy results from a syngeneic mouse model.
• Dataset is small (3.3 KB), facilitating quick download and initial inspection.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

Fredrik R. Zetterberg via figshare

Collection Method

Likely contains experimental results from drug discovery research, including synthesis, binding assays, and animal studies.

Freshness

Last updated 2026-04-29 11:20:37; freshness should be verified.